Tvardi Therapeutics, Inc. (TVRD) Stock Price & Analysis
Tvardi Therapeutics, Inc. (TVRD) fell 2.46% to USD 2.78 as of June 10, 2026 at 07:17 UTC, according to Nexqual real-time market data.
TVRD last closed at USD 2.85; the session ranged USD 2.75–3.01 on volume of 67,228 shares. Market capitalization is $26.08M, with a 52-week range of USD 2.75–43.65 (NCM). Source: Nexqual, June 10, 2026 at 07:17 UTC.
Key Statistics (as of June 10, 2026 at 07:17 UTC)
| Price | USD 2.78 |
|---|---|
| Change | ▼ 2.46% (down) |
| Previous Close | USD 2.85 |
| Open | USD 2.86 |
| Day Range | USD 2.75 – 3.01 |
| 52-Week Range | USD 2.75 – 43.65 |
| Volume | 67,228 shares |
| Market Cap | $26.08M |
| Exchange | NCM |
Technical Analysis (TVRD)
Nexqual's technical model rates TVRD "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:17 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.49 (neutral) |
| vs SMA50 | Below (USD 3.35) |
| MACD | -0.16 (negative) |
Analyst Ratings (TVRD)
Wall Street analysts rate TVRD "Buy" based on 7 analysts, with a mean price target of USD 8.29 (range USD 3–15), per Nexqual as of June 10, 2026 at 07:17 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 8.29 |
| High Target | USD 15 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 5 / 3 / 1 |
Earnings (TVRD)
| Next Earnings Date | 2026-05-08 |
|---|---|
| EPS Estimate | USD -0.63 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.78 vs est -0.57 ▼ miss |
| 2025-09-30 | USD -0.59 vs est -0.96 ▲ beat |
| 2025-06-30 | USD 0.51 vs est -0.39 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:17 UTC.
Financials & Fundamentals (TVRD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 1.2 |
| Current Ratio | 2.25 |
| Total Cash | $24.98M |
| Total Debt | $174,000 |
| Free Cash Flow | $-11.57M |
Source: Nexqual, June 10, 2026 at 07:17 UTC.
Financial Health Score (TVRD)
Nexqual rates Tvardi Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $25M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$22M |
| Efficiency | Mixed — No data |
Ownership (TVRD)
| Insider Ownership | +34.64% |
|---|---|
| Institutional Ownership | +28.93% |
| Shares Outstanding | 9.38M |
| Float | 6.46M |
| Short % of Float | +4.67% |
Source: Nexqual, June 10, 2026 at 07:17 UTC.
Leadership (TVRD)
Tvardi Therapeutics, Inc. is led by Imran Alibhai (age 48), CEO & Director, per Nexqual as of June 10, 2026 at 07:17 UTC.
| CEO & Director | Imran Alibhai (age 48) |
|---|---|
| CFO & Corporate Secretary | Dan Conn (age 57) |
| Co-Founder & Chairman of Scientific Advisory Board | Ronald A. DePinho (age 70) |
| Senior Vice President of R & D | Jeffrey Larson DABT (age 63) |
| Vice President of CMC | Yixin Chen (age 64) |
Major Backers & Investors (TVRD)
Notable institutional backers of Tvardi Therapeutics, Inc. include Slate Path Capital, LP, American Financial Group Inc., Fidelity, according to Nexqual as of June 10, 2026 at 07:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Slate Path Capital, LP | 7.51% |
| American Financial Group Inc. | 2.38% |
| Fidelity | 1.46% |
| Silvercrest Asset Management Group, LLC | 1.08% |
| Renaissance Technologies | 0.98% |
| Morgan Stanley | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.62% |
| BlackRock | 6.35% |
| Geode Capital | 1.94% |
| State Street | 1.04% |
Source: Nexqual, June 10, 2026 at 07:17 UTC.
From Tvardi Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
- The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings | USD 7.7 | ▲ 1.85% |
| XXII | 22nd Century Group, Inc | USD 0.37 | ▼ 21.17% |
| DOGP | Dogecoin Cash Inc. | USD 0.01 | ▼ 28.57% |
| CANN | TREES Corporation | USD 0.02 | ▲ 30.43% |
| AMMJ | American Cannabis Company, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:17 UTC. This page is informational and not investment advice.